- Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm (epinephrine) Sublingual Film
- Outlines the development strategy for the Company's next pipeline product candidate, AQST-108 (epinephrine) Topical Gel for the treatment of Alopecia areata
- Holds virtual investor day
WARREN, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today hosted a virtual investor day highlighting the Company's pipeline inclusive of Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, both product candidates emerging from the Company's Adrenaverse epinephrine prodrug platform. The event included presentations by members of the Aquestive management team and by distinguished key opinion leader J. David Farrar, PhD, Associate Professor, Immunology/Molecular Biology, UT Southwestern Medical Center.